Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7351691 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
US7208471 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
US6635618 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Sep, 2023
(7 months ago) | |
US7531623 | CUMBERLAND | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101575 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
US7700550 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
US7544364 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(2 years ago) | |
US8158580 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(2 years ago) | |
US7008923 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
US6872701 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Jun, 2021
(2 years ago) | |
US6858584 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(1 year, 8 months ago) |
Vibativ is owned by Cumberland.
Vibativ contains Telavancin Hydrochloride.
Vibativ has a total of 11 drug patents out of which 10 drug patents have expired.
Expired drug patents of Vibativ are:
Vibativ was authorised for market use on 11 September, 2009.
Vibativ is available in powder;intravenous dosage forms.
Vibativ can be used as method for treating bacterial infection, method of treating bacterial infections, method of treating a staphylococcal infection.
Drug patent challenges can be filed against Vibativ from 11 September, 2013.
The generics of Vibativ are possible to be released after 01 January, 2027.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-673) | Jun 21, 2016 |
New Chemical Entity Exclusivity(NCE) | Sep 11, 2014 |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 11 September, 2013
Market Authorisation Date: 11 September, 2009
Treatment: Method of treating bacterial infections; Method of treating a staphylococcal infection; Method for treating bacterial infection
Dosage: POWDER;INTRAVENOUS